Oxford Cancer Biomarkers
Oxford Cancer is developing and commercialising a suite of colorectal cancer biomarker tests to improve the current treatment pathway.
Financials
Estimates*
EUR | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
% growth | - | - | 112 % | 27 % | 4 % | 13 % | 11 % |
EBITDA | (<1m) | (1.8m) | (2.6m) | (1.5m) | - | - | - |
% EBITDA margin | (4751 %) | (1973 %) | (1353 %) | (628 %) | - | - | - |
Profit | (<1m) | (1.4m) | (2.5m) | (1.2m) | - | - | - |
% profit margin | (4952 %) | (1561 %) | (1322 %) | (512 %) | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | Seed | ||
N/A | Early VC | ||
* | £1.5m | Grant | |
Total Funding | CAD2.7m |
Recent News about Oxford Cancer Biomarkers
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.